Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen s CTO, Co-Founder Resigns

NEW YORK, June 13 – Nanogen said Wednesday that its chief technical officer and a company co-founders, Michael Heller, was leaving his position to take a job as a professor at an unnamed university.

"We are grateful for Dr. Heller's outstanding contributions to Nanogen over his approximately nine years here," Howard Birndorf, chairman of Nanogen’s board.

"He has assisted Nanogen in innumerable ways and has been a key inventor and contributor to the research and development of Nanogen's intellectual property and unique technologies.” Birndorf said.

Heller will remain an exclusive consultant to Nanogen, a San Diego-based maker of microelectronic DNA chips.

The company did not announce a replacement.

Over the past few months Nanogen has undergone a series of upper level management changes. Recently, Nanogen announced that Vance Randy White would replace founder Howard Birndorf as CEO. Birndorf will remain chairman of the company's board.

That appointment followed an April announcement that Nanogen had hired Gerald Wills, formerly the chief financial officer of Trega Biosciences, as its chief financial officer. Wills took over from Kieran Gallahue, who until then had been serving as both CFO and president. Gallahue is remaining in the role of president.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.